$DGX · QUEST DIAGNOSTICS INC
Quest Diagnostics reported Q3 2026 results with net revenues of $3.097 billion (+10.0% YoY), driven by 14.4% organic requisition volume growth. Adjusted diluted EPS was $3.00, up 15.4% from $2.60 a year ago. The company raised full-year 2026 guidance: revenues now expected at $12.065–$12.105 billion and adjusted diluted EPS at $11.25–$11.35, both above prior ranges.
- Q3 net revenues of $3.097 billion, up 10.0% YoY from $2.816 billion
- Q3 adjusted diluted EPS of $3.00, up 15.4% from $2.60 in prior year
- Organic requisition volume surged 14.4% YoY, while revenue per requisition declined 4.2%
- Full-year 2026 revenue guidance raised to $12.065–$12.105 billion (from $11.95–$12.05 billion)
- Full-year adjusted diluted EPS guidance raised to $11.25–$11.35 (from $11.05–$11.25)
Markets closed — no regular-session reaction yet; extended-hours move not captured here. At $26.34B market cap, the guidance raise and double-digit volume growth are likely to be received positively.
Quest delivered double-digit revenue and EPS growth with a guidance raise, signaling sustained demand across physician, hospital, and consumer channels despite pricing headwinds.
Quest's 14.4% organic volume growth reflects strong demand tailwinds from an aging population and increased consumer wellness testing, including a new Apple Health integration for direct-to-consumer lab panels.
Revenue per requisition declined 4.2% YoY, indicating pricing pressure that partially offsets the 14.4% volume surge. The filing also references an undisclosed incident described in a separate 8-K filed the same day.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.